Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder. Treatment is challenging; the armamentarium consists of topical corticosteroids, phototherapy, classic systemic treatments such as retinoids or immunosuppressive drugs, and most recently biologicals. However, the relative effectiveness of therapies is unclear. Our objective was to review the published literature on systemic treatment of PRP. A systematic review was conducted on PubMed and the Cochrane Library up to 5 September 2017. Studies evaluating any systemic treatments of PRP (except for historical treatments) were included. Overall, 182 studies met the predefined inclusion criteria, and reported on 475 patients and 652 courses of treatment. . This review balances effectiveness, side effects, experience, and drug costs in order to suggest a treatment regimen starting with isotretinoin as first-line, methotrexate as second-line and biologicals as third-line treatment for this difficult-to-treat dermatosis.
Introduction
Pityriasis rubra pilaris (PRP) is a rare, chronic papulosquamous condition with an incidence of 1 per 5,000 dermatologic patients in the United Kingdom [ 1 ] . Population-based prevalence is not available to our knowledge. Men and women are affected equally [ 1 ] . Pityriasis rubra pilaris is characterized clinically by follicular papules, orange-red erythema with areas of uninvolved skin (islands of sparing), and palmoplantar keratoderma [ 1 ] . Histopathology reveals alternating orthokeratosis and parakeratosis vertically and horizontally (checkerboard pattern), hypergranulosis, thick suprapapillary plates, broad rete ridges, sparse superfi cial perivascular infi ltrates, and follicular plugs [ 2 ] . According to Griffi ths, PRP can be classifi ed into fi ve types [ 1 ] . (1) Classical adult PRP accounts for 55 % of all patients, spreads caudally, and usually remits within three years. (2) Atypical adult PRP affects 5 % of patients and is characterized by ichthyosiform scaling and a chronic course. (3) Classic juvenile PRP occurs in 10 % of cases, with clinical features similar to those of type 1 PRP. (4) Circumscribed juvenile PRP is characterized by localized hyperkeratosis on the elbows and knees and affects 25 % of patients. (5) Atypical juvenile PRP occurs in 5 % of cases. Sclerosis-like palmar and plantar lesions and a chronic course are common. A sixth type that is HIV-related has been proposed [ 3 ] .
Treatment of PRP is challenging because the disease is often refractory to therapy and no guidelines are available to support clinicians with management decisions. The aim is to control the symptoms and prevent complications until -in half of all cases -spontaneous remission takes place [ 1 ] . However, chronic non-remitting disease courses have been described [ 1, 4 ] , highlighting the need for effective longterm control in these patients. Various therapies comprising topical application of corticosteroids, phototherapy, classic systemic treatments such as retinoids or immunosuppressive drugs, and most recently biologicals have been described with various effects [ 5, 6 ] . However, large clinical trials of high methodological quality are lacking due to the rarity of the disease, and treatment is based mainly on empirical data.
Several reviews have collected scientifi c evidence on the effectiveness of different therapies [5] [6] [7] [8] [9] [10] . However, the review processes were mostly performed in a non-systematic manner and/or with no quantitative analysis [ 5, 7, 8, 10 ] . Petrof and colleagues conducted a systematic review on the treatment of type 1 PRP with tumor necrosis factor (TNF)-α -antagonists [ 9 ] and found that this treatment modality may be benefi cial. Overall, the reviews report confl icting data on the effectiveness of systemic treatments.
This report is a systematic review of the literature on systemic treatment of PRP and provides a critical appraisal of the methodological quality of the reported studies.
Materials and Methods

Literature search
The design of the systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance (Table S1 online supplement) [ 11 ] . A systematic literature search was performed on the PubMed and Cochrane Library databases from their inception until 5 September 2017. The search term "pityriasis rubra pilaris" was used to identify all relevant articles. No restriction with regard to language or date of publication was applied. Further articles were retrieved from the reference lists of published reviews in order to complement these records.
Study identification
Only publications regarding patients diagnosed with PRP and treated systemically were considered eligible. The diagnostic certainty was categorized as level 1: typical clinical presentation, photographic evidence and histopathology fi ndings, or level 2: two out of these three criteria fulfi lled. Several historic therapies (retinol, antibiotics, tuberculostatic drugs, nicotinamide, and stanozolol) were excluded. The outcome of interest was the treatment success shown by photographic evidence and/or described in the publication. An excellent response (ER) was assumed if the disease severity decreased by 75 % or if the following terms were mentioned in the description: "complete" or "marked" response, "remission", "dramatic improvement", and "near clearance" or "complete clearance". Partial response (PR) represented an improvement of 25-75 % or respective phrasing (e.g. "some improvement"). An improvement of less than 25 % or exacerbation of the disease was considered a non-response (NR). If previous therapies were mentioned without further detail, discontinuation was assumed to be due to ineffectiveness. Screening was conducted at two levels by two of the authors (CK and RM): (a) titles and abstracts and (b) full-text articles. Discrepancies between authors were discussed until a consensus was reached.
Risk of bias assessment
The methodology of the included studies was assessed using the quality appraisal tool for case studies developed by Moga and colleagues [ 12 ] . This validated instrument consists of 18 checklist items referring to the study objective, population, intervention, outcome measures, statistical analysis, results and conclusions as well as confl icts of interest (Table S2 online supplement).
Data extraction and statistical analysis
Data were extracted with respect to the following characteristics: gender, age, nationality, type of PRP, diagnostic certainty, disease duration, and clinical presentation (for details see Table S3 online supplement) as well as treatment characteristics: therapy, dosage, concomitant therapy, previous therapy, primary therapeutic response (fi rst clear clinical improvement after starting systemic therapy), time until therapeutic response, fi nal response (clinical response at drug discontinuation or at time of last observation), drug survival, adverse events, and reason for discontinuation (for details see Table S4 online supplement). If a patient received the same medication twice, this was counted as two separate courses of treatment.
Statistical analysis and creation of fi gures was performed with commercially available software (Stata -Data Analysis and Statistical Software ® , version 14.1). Differences in effectiveness of individual therapies compared to acitretin (commonly applied as fi rst-line therapy [ 13 ] ) were tested using Pearson's Chi 2 test. Multivariate regression (OLS method) was performed to evaluate the infl uence on effectiveness of age, sex, type of PRP, number of previous treatments, and dosage.
Results
Overall, 743 records were identifi ed and 182 studies [ 3-5, 8, 13-190 ] were considered eligible for analysis ( Figure 1 ).
Assessment of risk of bias
Seventy percent of all case reports stated the objective of the study [3, 4, 8, 13-18, 20- -124, 126, 128-133, 136, 140, 142-144, 148, 149, 151-156, 158-160, 163-166, 168, 169, 174-182, 184, 185, 187-190] . Details of participants were provided in almost all publications. Only a minority reported a multicenter setting [ 4, 59, 76, 185 ] . Four out of fi ve studies described the treatment modality clearly [ 3-5, 8, 13-20, 22, 24, 25, 28-31, 33, 34, 36-39, 41, 42, 44-60, 62, 63, 65, 67-69, 71, 73-81, 83, 84, 86, 87, 89, 92-101, 104-109, 112, 113, 115-118, 120, 122-130, 132-139, 141-143, 145, 146, 148, 149, 151-165, 167-190 ] , but only 15 % applied clearly defi ned outcome measures [ 4, 15-17, 34, 41, 56, 59, 63, 68, 69, 75, 76, 83, 93, 95, 105, 108, 112, 123, 128, 149, 153, 168, 177, 185, 188, 189 ] . Statistical analysis was rarely performed [ 17, 76, 83, 188 ] . More than two thirds of all studies provided suffi cient information on follow-up [3, 5, 8, 14-16, 18, 19, 22, 24-26, 28, 29, 33, 34, 36- 161-165, 167, 175, 186, 187, 190 ] .
More than half of all studies reported between one third and two thirds of all checklist items [3-5, 8, 13-19, 22, 24, 26, 29, 31, 33, 34, 36-38, 41, 46-49, 51, 53, 55, 56, 58, 59, 63, 65, 68, 69, 72-76, 79, 80, 83, 84, 86, 89, 92, 93, 95, 98-100, 105, 108, 113, 115-118, 123-126, 128, 129, 132, 133, 136, 137, 141-143, 146, 151-156, 158, 161, 163, 165, 167-169, 174, 175, 177, 179-181, 184-190] , refl ecting an overall moderate quality (for details see supplementary online Tables S2 and S5) .
Patient characteristics
Overall, 475 patients with PRP (55.6 % male, 28.6 % female, gender not given in 15.8 %) with an average age of 45.3 years were identifi ed ( Table 1 ). The age distribution had peaks around 10 and 60 years of age and an additional sharp peak at the age of 40 years ( Figure 2 ). Most patients came from North America (55.2 %), followed by Europe (29.3 %) and Asia (8.8 %) . Patients with PRP type I were reported most commonly (72.7 %), followed by type III (9.8 %), V (6.3 %), II (4.6 %), VI (3.8 %), and IV (2.7 %). 83.5 % of all patients presented with erythroderma or suberythroderma,
a PubMed (n = 727), Cochrane (n = 9). b If more than one exclusion criterion applied, the record was assigned to the first applicable category in the order shown in the figure.
c Another reason for exclusion was insufficient information on treatment or outcome. 
Treatment characteristics
Treatment with retinoids was most commonly described (isotretinoin 21.5 % of all treatment courses, etretinate 14.4 %, acitretin 13.8 %, alitretinoin 1.5 %, other retinoids 7.2 %), followed by methotrexate (MTX; 15.8 %, Table 2 ). Of treatment with biologicals, most studies reported on infl iximab (5.8 % of all treatment courses), followed by etanercept (3.2 %), adalimumab (2.8 %), and ustekinumab (2.2 %). Retinoids were applied with a mean dosage of between 0.42 (alitretinoin) and 1.55 (isotretinoin) mg/kg body weight/day. Biologicals were usually administered according to the standard psoriasis regimen (Table 2 ) . Treatments were often combined with other systemic therapies (particularly acitretin, MTX or prednisolone) or phototherapy (37.0 % for retinoids and 44.4 % for biologicals). The number of previous systemic therapies or phototherapies was higher in patients receiving biologicals than in those receiving retinoids (1.9 vs. 0.3, respectively).
Treatment outcomes
A primary therapeutic response was reported in 28.4 % of all treatment courses (Table 3 ) . Overall, a therapeutic response (partial or excellent) was detected after 7.2 weeks (8.1 weeks for retinoid therapy and 4.6 weeks for biologicals). The fastest onset of action was observed in patients treated with adalimumab (3.5 weeks), followed by cyclosporine (3.7 weeks) and infl iximab (3.8 weeks), while etretinate was reported to take 19.6 weeks to have an effect. An excellent response was achieved in 42.0 % (225/514) of all patients receiving a retinoid. Within this group, alitretinoin was reported as most effective (72.7 % excellent response (8/11), Figure 4 , and p55 TNF receptor immunoadhesin (0 %, 0/1) were least effective. The effectiveness of treatment with TNF α inhibitors tended to be higher in TNF α -inhibitor-naïve patients than in patients previously exposed to TNF α inhibitors (68.2 %, 61/92 vs. 42.9 %, 3/7; p = 0.17). Classic immunosuppressive medication was successful in 33.1 % (MTX) and 11.8 % (cyclosporine) (Figure 4 c) . When compared to acitretin, which is commonly regarded as a fi rst-line therapy, signifi cantly higher rates of excellent response were observed with etretinate (p < 0.001), isotretinoin (p < 0.001), alitretinoin (p = 0.001), adalimumab (p = 0.02), etanercept (p = 0.001), infl iximab (p < 0.001), ustekinumab (p = 0.001), and secukinumab (p = 0.003), while cyclosporine (p = 0.03) and prednisolone (p < 0.001) were signifi cantly less effective. The excellent response rates of MTX and acitretin did not differ signifi cantly (Figure 4 ). The average drug survival (i.e. the time interval between initiation and discontinuation of a treatment) was 28.3 weeks (Table 3 ). Phototherapy comprises UVA1, UVB, PUVA, and "not specified phototherapy".
e Treatment with any TNF α inhibitor, not further specified.
f Antiretroviral therapy was only given to patients with PRP type VI (HIV-associated).
Abbr.: NA, not applicable; ND, not documented. , and any other systemic therapy (c), respectively. Differences in excellent response to individual therapies compared to that to acitretin, analyzed for significance using Chi 2 tests. * p < 0.05; ** p < 0.01; *** p < 0.001. ° Treatment with a TNF α inhibitor, not further specified. Abbr.: p55 rec. immunoad., p55 receptor immunoadhesion; MMF, mycophenolate mofetil; IVIGs, intravenous immunoglobulins.
Only a minority of patients (16.4 %) were still receiving medication at the time of the last observation. Overall, adverse events were reported as the reason for discontinuation in 8.6 % of patients (8.3 % for retinoids and 6.5 % for biologicals). 21.5 % of treatments were discontinued due to ineffectiveness (15.1 % for retinoids and 18.5 % for biologicals). The main reason for drug discontinuation was remission of disease (overall 33.6 %; 34.8 % for retinoids and 33.7 % for biologicals). The reason for discontinuation of therapy was not reported in 33.6 % of cases (38.5 % for retinoids and 21.7 % for biologicals).
Adverse events occurred in 26.4 % of all described treatment courses, but the probability was higher for retinoids (34.1 %) than for MTX (16.5 %) and biologicals (8.8 %). Patients treated with retinoids mainly complained about dryness of skin and/or mucosa (23.1 % of all patients treated with retinoids), or had elevated liver enzymes (2.6 %) or dyslipidemia (2.1 %). With biological therapies, adverse events were reported most frequently in patients treated with infl iximab (18.4 % adverse events, including infections and allergic reactions).
The results of multivariate regression adjusted for age, sex, type of PRP, number of previous treatments, and dosage showed an excellent response that was independent of patient age (Table 4 ) . Therapy with adalimumab was more effective in men than in women (p = 0.041). Retinoid therapy was less successful with PRP type II (isotretinoin, p = 0.037), type V (acitretin, p = 0.012) and type VI (isotretinoin, p < 0.001) than with PRP type I. The dosage and number of previous treatments had no signifi cant impact on excellent response rates of individual medications.
Discussion
To our knowledge this is the fi rst systematic review to collect evidence on all systemic treatments of PRP.
The age distribution of patients was consistent with data published in the literature [ 1 ] . Pityriasis rubra pilaris is commonly believed to affect both sexes equally [ 1 ] . However, we identifi ed a gender ratio of almost 2 : 1 (male: female), with gender not given in 15.8 % of patients. The distribution of different types of PRP was congruent with that reported by Griffi ths and colleagues [ 1 ] with the exception of a lower proportion of type IV PRP. This might be because the relatively mild manifestation (circumscribed areas at the elbows and knees) in patients with type IV PRP seldom requires systemic treatment [ 191 ] .
Most publications reported on treatment with retinoids, refl ecting their commonly accepted status as fi rst-line therapy [ 13 ] . However, due to similarities between PRP and psoriasis, a growing number of reports on treatment with biologicals has been published [ 192 ] . Adverse events occurred frequently in patients treated with retinoids (particularly dryness of skin and/or mucosa). However, dose adjustment and topical moisturizing therapy can limit these adverse events. Consequently, discontinuation of retinoids due to adverse events was rarely reported.
Retinoid therapy yielded a success rate of 42.0 %. Interestingly, acitretin was reported as inferior to alitretinoin, isotretinoin, etretinate and other retinoids, although it is often applied as fi rst-line treatment [ 13 ] . However, the different mean dosages (e.g. acitretin: 0.56 mg/kg body weight/d, isotretinoin: 1.55 mg/kg body weight/d) might infl uence effectiveness. The dosage of acitretin recommended for skin diseases is 0.5 mg/kg body weight/d [ 193 ] while the dosage for isotretinoin is usually 0.5-1 mg/kg body weight/d [ 194 ] . The relatively high dosage of isotretinoin in patients with PRP in this review might have contributed to its reported effectiveness. The signifi cantly shorter washout phase of isotretinoin and alitretinoin (5 weeks for both according to the prescribing information) than for acitretin (3 years) should also be considered in the clinical routine, particularly when prescribed to women with childbearing potential. Moreover, the effectiveness of alitretinoin has to be interpreted with caution due to the small number of published cases. In multivariate regression, treatment success was higher in type I PRP than in type II (atypical adult-onset), type V (atypical childhood-onset), or type VI (HIV-related) PRP, emphasizing the refractory nature of these subtypes.
In accordance with previously published reviews, treatment with other immunosuppressive medications (MTX or cyclosporine) was reported to be moderately effective with PRP [ 8, 10 ] . However, a recent review emphasized the role of MTX in the treatment of PRP due to positive response rates in two-thirds of 116 patients and good tolerability, and concluded that it should be considered as a fi rst-line treatment [ 195 ] . Moreover, patients seemed to rate therapy with MTX and therapy with retinoids as equally helpful in a larger case series [ 4 ] .
Treatment with biologicals was reported to be more effective than retinoid therapy (51.0 % vs. 42.0 % excellent response, p = 0.05) with a favorable risk profi le (8.8 % adverse events). The emerging importance of therapy with biologicals in the treatment of PRP is consistently emphasized in other reviews [ 8, 9 ] . A recent review recommends a treatment algorithm starting with retinoids (preferably isotretinoin) as fi rst-line therapy, immunosuppressive treatment (e.g. MTX) as second-line therapy, and treatment with biologicals (or apremilast in case of concomitant malignancy) as third-line therapy [ 6 ] . In our systematic review, patients naïve to TNF α antagonists showed a better response to TNF inhibitors than patients who had previously been treated with a TNF α antagonist; a similar phenomenon has been reported for other chronic infl ammatory diseases such as psoriasis [ 196 ] and The proportion of patients reaching excellent response with a specified systemic treatment was chosen as dependent variable. Treatments with alitretinoin, alefacept, antiretroviral therapy, apremilast, azathioprine, fumaric acid esters, intravenous immunoglobulins, mycophenolate mofetil, secukinumab, and p55 receptor immunoadhesin were omitted due to small numbers of treated patients. psoriatic arthritis [ 197 ] . Switching from a TNF α inhibitor to a biological with a different mechanism of action might therefore be worth considering in cases of treatment failure. The results of this systematic review should be interpreted with caution. Firstly, the stated effectiveness might be biased due to selective reporting and publication of positive outcomes. Secondly, only case reports and series of case reports were identifi ed and included in this review (as shown in the risk of bias assessment), and the methodological quality is therefore limited. In particular, placebo-controlled studies or double-blind head-to-head comparisons were lacking. Furthermore, treatments with several drugs such as alitretinoin, alefacept, efalizumab, secukinumab, azathioprine, fumaric acid esters, and apremilast are only reported for very few patients. Statements on effectiveness might therefore be biased. Moreover, type 1 PRP is reported to remit spontaneously within three years [ 1 ] . Therefore, it is not clear whether improvement of symptoms in this disorder is attributable to the effectiveness of treatment or to the natural course of the disease.
In conclusion, treatments with retinoids were found to be very effective. Among retinoids, isotretinoin appeared to be more effective than acitretin and has a shorter pharmacological half-life. Considering the limited evidence on treatment with alitretinoin we therefore suggest isotretinoin as fi rst-line treatment in PRP ( Figure 5 ). Classic immunosuppressive therapy of PRP with MTX has a well-known and acceptable risk profi le and yielded convincing (but possibly lower) effectiveness, which warrants its application as second-line treatment. Cyclosporine may be considered as a treatment option due to its rapid onset of action; however, small treatment numbers and its lower effi cacy as well as an unfavorable safety profile, particularly in older patients, limit its use in PRP [ 198 ] . This review provides evidence that therapy with biologicals has an effi cacy comparable to that of isotretinoin; however, it should be kept in mind that patient characteristics differ between groups, since patients receiving biologicals have previously received more systemic therapies. Biologicals might therefore be useful for clinicians as a third-line treatment for PRP, taking limited experience and increased cost into account. However, increasing experience and diminishing drug prices may lead to earlier application of biologicals in the therapeutic algorithm for PRP in the future. Phototherapy may be applied concomitantly to any systemic therapy except for cyclosporine. Likewise, combining different systemic treatments may be considered, provided that pharmacological drug interactions are kept in mind. As only acitretin and prednisolone have been authorized for PRP, other drugs can only be administered in an off-label setting. The very low prevalence of PRP makes it unlikely that larger clinical trials will be performed. Future research is desirable with larger cohorts of patients and a prospective design, for example in a registry.
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